88341-06-4

Basic information

• Product Name: 1-(Benzo[b]thiophen-4-yl)ethanone
• Synonyms: 1-(Benzo[b]thiophen-4-yl)ethanone;Ethanone, 1-(benzo[b]thien-4-yl)-
• CAS NO: 88341-06-4
• Molecular Formula: C10H8OS
• Molecular Weight: 176.23492
• Mol File: 88341-06-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(Benzo[b]thiophen-4-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Benzo[b]thiophen-4-yl)ethanone(88341-06-4)
• EPA Substance Registry System: 1-(Benzo[b]thiophen-4-yl)ethanone(88341-06-4)

Safety Data

• Hazardous Substances Data: 88341-06-4(Hazardous Substances Data)

Usage

Appearance

Yellow crystalline solid

Melting point

72-74°C

Uses

a. Intermediate in the synthesis of pharmaceuticals and organic compounds
b. Production of dyes and pigments due to aromatic properties
c. Potential applications in organic electronic devices and materials due to electronic and optical properties

Safety

Handle with care, may be hazardous if not used properly

Upstream product

• 10134-95-9 benzothiophen-4-carboxic acid 
• 195520-04-8 benzo[b]thiophen-4-yl trifluoromethanesulfonate 
• 111-34-2 -butyl vinyl ether 
• 3610-02-4 4-hydroxybenzothiophene 
• 5118-13-8 4-bromobenzo[b]thiophene 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 17347-34-1 benzo[b]thiophene-4-carbonitrile 
• 75-16-1 methylmagnesium bromide 

Relevant articles and documents

2-METHYL-AZA-QUINAZOLINES

The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS

Novel tricyclic compounds of Formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS

Novel tricyclic compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing osteoporosis and similar conditions. The compounds are effective as calcium sensing receptor antagonists. Pharmaceutical compositions and methods of treatment are also included.

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle optionally substituted with substituents (1 to 4 in number) as defined in R14; with R1, R2, R3, R4, R5, R6, R7, R8, and R14 defined herein.

Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents

The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds of Formula (I) including pharmaceutically acceptable salts thereof in which have affinity for 5-HT1A receptors and which inhibits neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, as an aid to smoking cessation and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage.

Conformational Analysis of Organic Carbonyl Compounds. Part 3. A 1H and 13C nuclear Magnetic Resonance Study of Formyl and Acetyl Derivatives of Benzothiophen

The conformational analysis of formyl and acetyl derivatives of benzothiophen was carried out by employing n.m.r. chemical shifts (1H and 13C) and coupling constants.By measuring the lanthanide-induced shifts (LIS) and simulating experimental chemical shifts the relative conformer stability was determined.The results show that all the molecules examined are present almost completely in the Z-conformation and that the stabilization of one conformer in this heterocyclic system seems due almost exclusively to the mesomeric interaction originating in the trans-arrangement of the C=O bond and the C=C bond having the higher double-bond character.